Nephropathy Clinical Trial
Official title:
Evaluating the Protective Effect of Pentoxifylline on Contrast Induced Nephropathy
Contrast induced nephropathy (CIN) is of great concern when using contrast media in the new era of medicine. CIN is defined as 25-50% relative increase, 0.5-1 absolute increase in serum creatinin value or 25% fall in GFR. The incidence of CIN is found to be 0% to 10% in general population and up to 50% in high risk population. High risk patients include those with chronic kidney disease (GFR<60 ml/min/1.73 m²) Diabetes Mellitus, congestive heart failure, anemia and advanced age. Amount and kind of contrast medium and decreased circulating blood volume are other important predictors of CIN. 50% of cases of CIN happen within 24 hours of contrast injection. Maximum creatinin levels are reached between 48-72 hours. It usually returns to previous levels in 7-10 days. Suggested mechanisms are renal vasoconstriction and tubular injury. N-acetylcysteine and hydration are proved to be protective against CIN and theophylline may have a role. In this study, it is hypothesized that pentoxifylline, a dimethylxanthine, can also protect renal cells from CIN. It has been observed that pentoxifylline improves oxygen delivery to ischemic tissues, diminishes oxidative damage to renal tissue and may also scavenge free radicals. Percutaneous coronary intervention is assumed a high risk procedure for developing CIN as the amount of contrast used in PCI is remarkable. Therefore, the patients undergoing PCI were selected for the trial. A prospective randomized trial will be conducted on patients undergoing PCI.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Outcomes Assessor), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Recruiting |
NCT01448889 -
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
|
N/A | |
| Active, not recruiting |
NCT05026021 -
Prediction of BKvirus Nephropathy Risk by the NEPHROVIR Method in Kidney Transplant Patients With BKvirus Viremia
|
||
| Completed |
NCT02470247 -
Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients
|
N/A | |
| Recruiting |
NCT05511779 -
Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
|
Phase 2 | |
| Active, not recruiting |
NCT03584217 -
Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Completed |
NCT02575092 -
The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05839314 -
Effect of Huaier Granule on the Treatment of Idiopathic Membranous Nephropathy
|
Phase 4 | |
| Completed |
NCT01638663 -
Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
|
Phase 2 | |
| Completed |
NCT01213498 -
The Effects of Atorvastatin on the Nitric Oxide-system in Patients With Non-diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01208701 -
The Effects of Atorvastatin on the Nitrogen Oxide-system in Patients With Type 2 Diabetes and Nephropathy
|
Phase 2 | |
| Completed |
NCT01214746 -
The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man
|
Phase 2 | |
| Active, not recruiting |
NCT00655330 -
Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
|
N/A | |
| Completed |
NCT00308347 -
A Research Study to Evaluate the Renal (Kidney) Protective Effects of Losartan in Patients With Non-insulin Dependent Diabetes (0954-147)(COMPLETED)
|
Phase 3 | |
| Terminated |
NCT00579995 -
A Prospective, Randomized TrialComparing Oral N-Acetylcysteine and Intravenous Sodium Bicarbonate
|
N/A | |
| Completed |
NCT05986474 -
Development of Synthetic Medical Data Generation Technology to Predict Postoperative Complications
|
||
| Recruiting |
NCT03886714 -
Screening for Fabry Disease in Renal Transplantation
|
||
| Recruiting |
NCT06325059 -
The Role of Renal Progenitors and Polyploid Tubular Cell Response in Glomerular and Tubular Diseases
|
N/A |